行情

ABBV

ABBV

艾伯维
NYSE

实时行情|Nasdaq Last Sale

70.51
-0.32
-0.45%
盘后: 70.45 -0.06 -0.09% 19:52 09/13 EDT
开盘
71.15
昨收
70.83
最高
71.51
最低
70.48
成交量
813.56万
成交额
--
52周最高
96.60
52周最低
62.66
市值
1,042.48亿
市盈率(TTM)
25.41
分时
5日
1月
3月
1年
5年

分析师评级

13位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ABBV 新闻

  • Your 57 September S&P 500 Dividend Aristocrats
  • Seeking Alpha - Article.1天前
  • Coalition urges FTC block to ABBV-AGN deal
  • seekingalpha.2天前
  • Dividend Growth ETFs for Long Term Investors
  • Zacks.2天前
  • Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
  • Zacks.2天前

更多

所属板块

制药
-0.54%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

ABBV 简况

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
展开

Webull提供AbbVie Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。